ArticleBreast (Edinburgh, Scotland)2026
Early termination of clinical trials enrolling patients with breast cancer: Reasons, determinants, and temporal patterns.
Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe occurrence of clinical trial termination before planned completion (or "early termination" [ET]) remains poorly characterized in the breast cancer field. This study investigates the reasons, determinants, and temporal patterns of ET in breast cancer trials.
methodsWe conducted a cross-sectional study using the Aggregate Analysis of ClinicalTrials.gov (AACT) database, including breast cancer trials initiated between 2001 and 2025. Reasons for ET were identified and classified into predefined categories. Factors associated with ET were evaluated using multivariable logistic regression, and temporal patterns were assessed using competing risk analysis and a multivariable Fine-Gray subdistribution hazard model.
resultsA total of 5251 trials were included. "Poor accrual" was the most common reason for ET (39.2%), followed by "sponsor decision or strategic reasons" (22.4%) and "operational or management issues" (13.4%). "Poor accrual" was the leading cause of ET among phase 2 and 3 trials, academic-sponsored studies, and single-center trials, whereas "sponsor decision or strategic reasons" predominated among phase 1 trials, industry-sponsored studies, and trials conducted globally. In multivariable logistic regression analyses, phase 2 trials had a higher likelihood of ET (OR = 1.48; P < .001), whereas multicenter studies (OR = 0.70; P < .001) and trials with non-treatment purposes (OR = 0.61; P < .001) had a lower likelihood of ET. Similar patterns were observed in the Fine-Gray model.
conclusionsEarly termination of breast cancer trials is a heterogeneous phenomenon, with distinct patterns based on study characteristics. Tailored strategies to improve trial feasibility, participant recruitment, and operational planning may reduce the risk of ET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.